New ADHD Medication

FDA approves AD/HD patch for adolescent use.
The AP (7/7) reports, "Shire PLC said Tuesday that US regulators approved its attention deficit hyperactivity disorder patch Daytrana [methylphenidate transdermal] for use in adolescents age 13 to 17." The FDA previously "approved Daytrana in April 2006 for use in children age six to 12." The patch "is sold in strengths of 10 milligrams, 15 milligrams, 20 milligrams, and 30 milligrams, and is designed to be worn for nine hours."
The Philadelphia Inquirer (7/7, Rudolph) notes that the patch is "designed to be used in conjunction with psychological, educational and other measures."